The treatment landscape for CLL has seen groundbreaking changes with the introduction of targeted therapies, specifically Bruton’s tyrosine kinase (BTK) and B-cell lymphoma 2 (Bcl-2) inhibitors (Herman et al., 2011; Souers et al., 2013; Herman et al., 2010). Here, BTK is linked to B-cell chronic lymphocytic leukemia.